[go: up one dir, main page]

RU2018104278A3 - - Google Patents

Download PDF

Info

Publication number
RU2018104278A3
RU2018104278A3 RU2018104278A RU2018104278A RU2018104278A3 RU 2018104278 A3 RU2018104278 A3 RU 2018104278A3 RU 2018104278 A RU2018104278 A RU 2018104278A RU 2018104278 A RU2018104278 A RU 2018104278A RU 2018104278 A3 RU2018104278 A3 RU 2018104278A3
Authority
RU
Russia
Application number
RU2018104278A
Other versions
RU2744267C2 (ru
RU2018104278A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018104278A publication Critical patent/RU2018104278A/ru
Publication of RU2018104278A3 publication Critical patent/RU2018104278A3/ru
Application granted granted Critical
Publication of RU2744267C2 publication Critical patent/RU2744267C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2018104278A 2015-07-06 2016-07-06 Оксистеролы и способы их применения RU2744267C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562189048P 2015-07-06 2015-07-06
US62/189,048 2015-07-06
US201662280394P 2016-01-19 2016-01-19
US62/280,394 2016-01-19
PCT/US2016/041168 WO2017007836A1 (en) 2015-07-06 2016-07-06 Oxysterols and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021100620A Division RU2021100620A (ru) 2015-07-06 2016-07-06 Оксистеролы и способы их применения

Publications (3)

Publication Number Publication Date
RU2018104278A RU2018104278A (ru) 2019-08-06
RU2018104278A3 true RU2018104278A3 (ru) 2019-10-31
RU2744267C2 RU2744267C2 (ru) 2021-03-04

Family

ID=57686105

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018104278A RU2744267C2 (ru) 2015-07-06 2016-07-06 Оксистеролы и способы их применения
RU2021100620A RU2021100620A (ru) 2015-07-06 2016-07-06 Оксистеролы и способы их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2021100620A RU2021100620A (ru) 2015-07-06 2016-07-06 Оксистеролы и способы их применения

Country Status (30)

Country Link
US (4) US10201550B2 (ru)
EP (3) EP4609866A3 (ru)
JP (4) JP2018519351A (ru)
KR (2) KR20240137111A (ru)
CN (2) CN113292623A (ru)
AU (3) AU2016289967B2 (ru)
BR (2) BR112018000129B1 (ru)
CA (1) CA2991214C (ru)
CO (1) CO2018000660A2 (ru)
CY (1) CY1124496T1 (ru)
DK (2) DK3828194T3 (ru)
ES (2) ES2865258T3 (ru)
FI (1) FI3828194T3 (ru)
HR (1) HRP20210526T8 (ru)
HU (1) HUE053778T2 (ru)
IL (2) IL305404A (ru)
LT (1) LT3319611T (ru)
MA (2) MA55097A (ru)
MD (1) MD3319611T2 (ru)
MX (2) MX390302B (ru)
PE (1) PE20180483A1 (ru)
PH (2) PH12021551134A1 (ru)
PL (2) PL3319611T3 (ru)
PT (2) PT3828194T (ru)
RS (1) RS61718B1 (ru)
RU (2) RU2744267C2 (ru)
SG (1) SG10202010553XA (ru)
SI (1) SI3319611T1 (ru)
SM (1) SMT202100226T1 (ru)
WO (1) WO2017007836A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE062616T2 (hu) 2011-09-08 2023-11-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásaik
RU2684103C2 (ru) 2013-03-13 2019-04-04 Сейдж Терапьютикс, Инк. Нейроактивные стероиды и способы их применения
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10238664B2 (en) 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
EP4609866A3 (en) 2015-07-06 2025-10-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3319612T3 (pl) 2015-07-06 2021-12-20 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
WO2017007832A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
RU2754130C2 (ru) * 2016-04-01 2021-08-27 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA3029900A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA46351A (fr) * 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
TWI836485B (zh) 2016-10-18 2024-03-21 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
JP7118957B2 (ja) 2016-10-18 2022-08-16 セージ セラピューティクス, インコーポレイテッド オキシステロールおよびその使用方法
US11458146B2 (en) 2017-01-13 2022-10-04 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
EP4351588A1 (en) 2021-06-11 2024-04-17 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease
CN113667734B (zh) * 2021-07-16 2022-05-24 四川大学华西医院 Shank3片段序列甲基化检测试剂在制备精神分裂症诊断试剂盒中的用途
US20240368214A1 (en) * 2021-08-25 2024-11-07 Sage Therapeutics, Inc. Positive nmda-modulating compounds and methods of use thereof
EP4430056A1 (en) * 2021-11-10 2024-09-18 Umecrine AB 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
WO2023143399A1 (zh) * 2022-01-28 2023-08-03 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
WO2024229297A1 (en) * 2023-05-02 2024-11-07 Sage Therapeutics, Inc. Lymphatic system-targeting compounds
TW202508555A (zh) * 2023-07-27 2025-03-01 大陸商珂闌(上海)醫藥科技有限公司 甾類化合物、其製備方法和應用
WO2025020190A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
CN119371475B (zh) * 2023-07-27 2025-11-04 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
WO2025221732A1 (en) * 2024-04-15 2025-10-23 Sage Therapeutics, Inc. Nmda receptor-modulating compounds and methods of use thereof

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2259698A (en) 1938-05-07 1941-10-21 Rare Chemicals Inc Physiologically effective substance and process of preparing same
US2594323A (en) 1948-07-22 1952-04-29 Upjohn Co 24-substituted delta 5-cholene-3, 24-diols
US2673206A (en) 1950-06-07 1954-03-23 Schering Corp 25-ethinyl steroids
US3079385A (en) 1961-01-24 1963-02-26 Roussel Uclaf Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
JPS5324071B2 (ru) 1974-04-30 1978-07-18
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
CH628907A5 (en) 1975-10-10 1982-03-31 Hoffmann La Roche Process for the preparation of 24,25-dihydroxycholesterol derivatives
JPS5840960B2 (ja) 1976-12-28 1983-09-08 帝人株式会社 ヒドロキシコレステロ−ル立体異性体間の相互変換法
US4183852A (en) 1977-07-18 1980-01-15 Kaiser Emil T Process for preparing 25-hydroxycholesterol
JPS54163565A (en) 1978-06-09 1979-12-26 Teijin Ltd 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
US4174345A (en) 1978-08-01 1979-11-13 Kaiser Emil T Synthesis of steroids
US4269777A (en) 1979-05-21 1981-05-26 Wisconsin Alumni Research Foundation Isotopically labeled vitamin D derivatives and processes for preparing same
JPS5735597A (en) 1980-08-13 1982-02-26 Teijin Ltd 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
US4358406A (en) 1981-07-27 1982-11-09 Wisconsin Alumni Research Foundation 26,26,26,27,27,27-Hexafluoro-1α,25-dihydroxycholecalciferol and process for preparing same
JPS61254599A (ja) 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
DE3664909D1 (en) 1985-05-30 1989-09-14 Taisho Pharmaceutical Co Ltd Vitamin d3 derivatives
JPS62187485A (ja) 1986-02-13 1987-08-15 Teijin Ltd 24,25−エポキシコレステロ−ル類の製造法
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
AU609927B2 (en) 1987-08-25 1991-05-09 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU698834B2 (en) 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
IL110309A0 (en) 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
DE4338316A1 (de) 1993-11-10 1995-05-11 Jenapharm Gmbh Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AU691905B2 (en) 1994-02-14 1998-05-28 Purdue Pharma Ltd. Androstanes and pregnanes for allosteric modulation of GABA receptor
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5595996A (en) 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
EP0808325B1 (en) 1994-11-23 2001-01-17 Cocensys, Inc. Androstane and pregnane series for allosteric modulation of gaba receptor
JPH08268917A (ja) 1995-03-31 1996-10-15 D D S Kenkyusho:Kk 癌組織への移行性の高い制癌剤
US5925630A (en) * 1995-06-06 1999-07-20 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
WO1997000884A1 (en) 1995-06-23 1997-01-09 Novo Nordisk A/S Meiosis regulating compounds
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
US5888996A (en) 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
EP0840612A1 (en) 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US5841272A (en) 1995-12-20 1998-11-24 Sundstrand Corporation Frequency-insensitive current sensor
WO1997042215A1 (en) 1996-05-06 1997-11-13 Bionumerik Pharmaceuticals, Inc. Process for preparing 27-hydroxy cholesterol and related derivatives
JPH09328498A (ja) 1996-06-10 1997-12-22 Teijin Ltd 24,25−ジヒドロキシコレステロールの製造法およびその合成中間体
AU3967297A (en) 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US6122371A (en) 1997-07-22 2000-09-19 Atwell; Ronald C. Apparatus for protecting coin-operated telephones from vandalism and larceny
CA2331299A1 (en) 1998-05-11 1999-11-18 Novo Nordisk A/S Substituted guanidines and diaminonitroethenes, their preparation and use
KR20010043558A (ko) 1998-05-13 2001-05-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 감수분열 조절 화합물
US8541600B2 (en) 1998-11-24 2013-09-24 Harbor Therapeutics, Inc. 11-aza, 11-thia and 11-oxa sterol compounds and compositions
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
PL351438A1 (en) 1999-04-29 2003-04-22 Purdue Pharma Ltd 3α−hydroxy−3β methoxymethyl−21−heterocycle substituted steroids with anesthetic activity
US6376530B1 (en) * 1999-05-10 2002-04-23 Merck & Co., Inc. Cyclic amidines useful as NMDA NR2B antagonists
GB9910934D0 (en) 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
CN1111167C (zh) 1999-10-22 2003-06-11 中国科学院上海有机化学研究所 3β-羟基-5-胆烯酸酯类衍生物、合成方法及其用途
CN1098273C (zh) 1999-11-12 2003-01-08 中国科学院上海有机化学研究所 高立体选择性的合成24r,25-和24s,25-二羟基甾体化合物
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0019290D0 (en) 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
ES2296928T3 (es) 2001-05-03 2008-05-01 The University Of Chicago Receptores x hepaticos.
JP2005508368A (ja) 2001-11-08 2005-03-31 ザ ユニバーシティー オブ シカゴ 高コレステロール濃度に関連した疾患の治療方法
JP2005511713A (ja) 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
KR20100093621A (ko) 2002-03-27 2010-08-25 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 용도
KR101130212B1 (ko) 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
GB0216621D0 (en) * 2002-07-17 2002-08-28 Imaging Res Solutions Ltd Imaging compounds
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
AU2003291074A1 (en) * 2002-11-22 2004-06-18 Merck & Co., Inc. 2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as NR2B receptor antagonists
AU2003288231A1 (en) 2002-12-13 2004-07-09 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
FR2850023B1 (fr) 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
GB0403889D0 (en) 2004-02-21 2004-03-24 Univ Edinburgh Uses of er-beta modulators
WO2006037016A2 (en) 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
US20070032464A1 (en) 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
CA2585471A1 (en) 2004-11-01 2006-05-11 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
AU2007217366A1 (en) 2006-02-27 2007-08-30 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
CN101164540A (zh) 2006-08-03 2008-04-23 中山大学 海洋甾体化合物在制备治疗神经元损伤药物中的应用
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
US8273747B2 (en) 2006-11-02 2012-09-25 Curis, Inc. Small organic molecule regulators of cell proliferation
DK2711371T3 (en) 2006-11-21 2018-04-16 Asarina Pharma Ab Use of Pregnancy and Androstan Steroids in the Preparation of a Pharmaceutical Composition for the Treatment of CNS Disorders
NZ599643A (en) 2007-06-20 2013-11-29 Auspex Pharmaceuticals Inc Substituted N-aryl pyridinones as fibrotic inhibitors
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
US20110118353A1 (en) 2007-11-06 2011-05-19 N. V. Organon Method of hormone suppression in humans
CN101951915A (zh) 2007-12-03 2011-01-19 加利福尼亚大学董事会 用于刺猬蛋白信号、骨诱导、抗脂肪形成和wnt信号的激活的氧固醇
WO2009090063A1 (en) 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
EP2244577B1 (en) 2008-01-25 2012-10-31 Merck Sharp & Dohme Corp. Quinolizidinone m1 receptor positive allosteric modulators
SG195568A1 (en) 2008-05-09 2013-12-30 Univ Emory Nmda receptor antagonists for the treatment of neuropsychiatric disorders
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
WO2010088414A2 (en) 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
JP2013500986A (ja) 2009-07-29 2013-01-10 ザ・ユニバーシティ・オブ・シカゴ 肝臓x受容体アゴニスト
WO2011028794A2 (en) 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (fr) 2009-12-02 2015-10-16 Assist Publ Hopitaux Marseille Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
WO2011092127A1 (en) 2010-01-26 2011-08-04 Bayer Schering Pharma Aktiengesellschaft 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201008047D0 (en) * 2010-05-14 2010-06-30 Ge Healthcare Ltd Method of synthesis
US20120035156A1 (en) 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
US8969525B2 (en) 2010-11-09 2015-03-03 Enzo Life Sciences, Inc. Hydroxycholesterol immunoassay
US20150031655A1 (en) 2011-04-15 2015-01-29 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
US20140335050A1 (en) 2011-05-27 2014-11-13 The General Hospital Corporation Methods, compositions, and kits for the treatment of cancer
WO2013019711A2 (en) 2011-07-29 2013-02-07 The Regents Of The University Of California NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
HUE062616T2 (hu) 2011-09-08 2023-11-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásaik
CN103842356B (zh) 2011-10-07 2017-03-15 武田药品工业株式会社 用于治疗神经变性疾病的1‑芳基羰基‑4‑氧‑哌啶化合物
CN104136452A (zh) 2011-10-14 2014-11-05 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
US20150119327A1 (en) 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
WO2014025942A1 (en) 2012-08-09 2014-02-13 Emory University Nmda receptor modulators and uses related thereto
WO2014028942A2 (en) 2012-08-17 2014-02-20 Trueex Group Llc Interoffice bank offered rate financial product and implementation
HUE039057T2 (hu) 2012-12-18 2018-12-28 Univ Washington Kezelési eljárásokban alkalmazható neuroaktív 19-alkoxi-17-szubsztituált szteroidok
CN105073119A (zh) 2013-01-23 2015-11-18 司菲埃拉制药私人有限公司 用于线粒体生物发生和与线粒体功能障碍或耗竭相关的疾病的新颖11β-羟基类固醇化合物
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN119269811A (zh) 2013-03-13 2025-01-07 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
RU2684103C2 (ru) 2013-03-13 2019-04-04 Сейдж Терапьютикс, Инк. Нейроактивные стероиды и способы их применения
KR20160060688A (ko) 2013-09-25 2016-05-30 반 안델 리서치 인스티튜트 고도로 강력한 글루코코르티코이드
CN112826930A (zh) 2014-02-08 2021-05-25 豪夫迈·罗氏有限公司 治疗阿尔茨海默氏病的方法
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10238664B2 (en) 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
US10016095B2 (en) * 2014-10-03 2018-07-10 Progressive International Corporation Salad spinner
IL292465B2 (en) 2014-10-07 2025-06-01 Sage Therapeutics Inc Neuroactive compounds and methods of use thereof
EP4609866A3 (en) 2015-07-06 2025-10-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3319612T3 (pl) 2015-07-06 2021-12-20 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
WO2017007832A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
GB2557875A (en) 2015-09-02 2018-07-04 Univ Swansea Diagnostic methods and kits
RU2754130C2 (ru) 2016-04-01 2021-08-27 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA3029900A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
NZ790186A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C7, C12, and C16 substituted neuroactive steroids and their methods of use
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
JP7118957B2 (ja) 2016-10-18 2022-08-16 セージ セラピューティクス, インコーポレイテッド オキシステロールおよびその使用方法
TWI836485B (zh) 2016-10-18 2024-03-21 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
AU2018234828A1 (en) 2017-03-15 2019-09-19 Modernatx, Inc. Lipid nanoparticle formulation
WO2018237350A1 (en) 2017-06-23 2018-12-27 Intercept Pharmaceuticals, Inc. METHODS AND INTERMEDIATES FOR PREPARING BILARY ACID DERIVATIVES
US20190160078A1 (en) 2017-11-10 2019-05-30 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disorders
EP4333856A1 (en) 2021-05-04 2024-03-13 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of mild cognitive impairment associated with parkinson's disease
EP4351588A1 (en) 2021-06-11 2024-04-17 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
US20240277733A1 (en) 2024-08-22
WO2017007836A1 (en) 2017-01-12
CO2018000660A2 (es) 2018-07-10
JP2021054864A (ja) 2021-04-08
AU2024200268A1 (en) 2024-02-01
KR20180026743A (ko) 2018-03-13
CN108135912A (zh) 2018-06-08
SI3319611T1 (sl) 2021-08-31
NZ777726A (en) 2024-05-31
IL256710A (en) 2018-03-29
MX376833B (es) 2025-03-07
RU2021100620A (ru) 2021-01-29
IL256710B2 (en) 2024-01-01
HUE053778T2 (hu) 2021-07-28
HRP20210526T1 (hr) 2021-05-28
DK3828194T3 (da) 2025-06-30
JP2025026573A (ja) 2025-02-21
RU2744267C2 (ru) 2021-03-04
JP2022120062A (ja) 2022-08-17
EP4609866A2 (en) 2025-09-03
RS61718B1 (sr) 2021-05-31
AU2021218228B2 (en) 2023-11-16
CA2991214C (en) 2024-04-30
MX2018000282A (es) 2018-03-08
PT3319611T (pt) 2021-04-22
BR112018000129A2 (pt) 2018-09-04
MX2020011449A (es) 2022-02-28
FI3828194T3 (fi) 2025-07-17
EP3319611A1 (en) 2018-05-16
US12268697B2 (en) 2025-04-08
RU2018104278A (ru) 2019-08-06
PL3319611T3 (pl) 2021-07-12
MX390302B (es) 2025-03-19
ES3035617T3 (en) 2025-09-05
AU2016289967A1 (en) 2018-02-01
DK3319611T3 (da) 2021-04-12
SMT202100226T1 (it) 2021-05-07
KR20240137111A (ko) 2024-09-19
IL256710B1 (en) 2023-09-01
US10201550B2 (en) 2019-02-12
CN113292623A (zh) 2021-08-24
CN108135912B (zh) 2021-07-02
EP4609866A3 (en) 2025-10-22
JP7602513B2 (ja) 2024-12-18
EP3828194A1 (en) 2021-06-02
PE20180483A1 (es) 2018-03-07
KR102703602B1 (ko) 2024-09-06
BR112018000129B1 (pt) 2024-01-09
PT3828194T (pt) 2025-07-17
MD3319611T2 (ro) 2021-06-30
US20190125764A1 (en) 2019-05-02
ES2865258T3 (es) 2021-10-15
US20180200267A1 (en) 2018-07-19
US10765685B2 (en) 2020-09-08
US20210145848A1 (en) 2021-05-20
AU2016289967B2 (en) 2021-09-09
CY1124496T1 (el) 2022-07-22
EP3828194B1 (en) 2025-04-16
BR122021005552B1 (pt) 2024-01-02
PL3828194T3 (pl) 2025-09-22
AU2021218228A1 (en) 2021-09-09
PH12018500065B1 (en) 2022-11-04
PH12021551134A1 (en) 2024-03-25
PH12018500065A1 (en) 2018-07-09
MA42410A (fr) 2018-05-16
EP3319611B1 (en) 2021-01-20
MA42410B1 (fr) 2021-04-30
NZ738847A (en) 2024-05-31
EP3319611A4 (en) 2019-03-06
BR122023021450A2 (pt) 2023-12-26
SG10202010553XA (en) 2020-12-30
JP2018519351A (ja) 2018-07-19
MA55097A (fr) 2022-01-05
HRP20210526T8 (hr) 2021-08-20
LT3319611T (lt) 2021-05-10
IL305404A (en) 2023-10-01
CA2991214A1 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
RU2018104278A3 (ru)
BR112016019305A2 (ru)
BR112018005033A2 (ru)
BR0009373B1 (ru)
BR0000126B1 (ru)
BR0005041B1 (ru)
BR0004687B1 (ru)
BR0003928B1 (ru)
BR0003751B1 (ru)
BR0003746B1 (ru)
BR0003686B1 (ru)
BR0009182B1 (ru)
BR0003401B1 (ru)
BR0003208B1 (ru)
BR0003189B1 (ru)
BR0003166B1 (ru)
BR0002874B1 (ru)
BR0002802B1 (ru)
BR0002694B1 (ru)
BR0002435B1 (ru)
CN303070361S (ru)
CN303068724S (ru)
BR0002402B1 (ru)
CN303068714S (ru)
BR0005085B1 (ru)